Lenvatinib/Everolimus in Refractory mRCC

Managing Patients on Lenvatinib/Everolimus in mRCCПодробнее

Efficacy and Safety of Lenvatinib/Everolimus in mRCCПодробнее

Practical Experience With Lenvatinib/Everolimus in RCCПодробнее

Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCCПодробнее

Dr. Choueiri on FDA Approval of Lenvatinib/Everolimus in RCCПодробнее

Lenvatinib increases progression free survival with everolimus in metastatic renal cell carcinomaПодробнее

Lenvatinib and Everolimus for Advanced RCCПодробнее

Lenvatinib and Everolimus in Relapsed/Refractory mRCCПодробнее

Dr. Agarwal on the Combination of Lenvatinib and Everolimus in mRCCПодробнее

Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinomaПодробнее

Phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinomaПодробнее

Three-arm trial of lenvatinib and everolimus for metastatic renal cell carcinomaПодробнее

Second-Line Combination Therapy in mRCCПодробнее

IKCS 2020: Phase 2 trial of lenvatinib at 2 starting doses+ everolimus in renal cell carcinoma (RCC)Подробнее

Q-TWiST of lenvatinib + everolimus in advanced RCCПодробнее

Dr. Funahashi on Enhanced Activity With Lenvatinib/Everolimus Combo in RCCПодробнее

Dr. Hutson on Lenvatinib/Everolimus Combo in RCCПодробнее

The Role of Lenvatinib in Advanced RCCПодробнее